Lifeboat Foundation

In a clinical trial, patients on the highest injected dose had 30 percent less cognitive decline over time than people on a placebo.

If you are able to get to Leiden there is an event in support of Lifespan.io on September 29, 12:00 AM – 2:00 PM CEST.

Ending aging and getting rid of its associated conditions is one of humanity’s most ancient dreams. Some of our earliest myths are about heroes going on a quest to find a way to make the whole of mankind forever young. With the current progress in aging research, this is not a dream anymore. In laboratories around the globe, researchers are conducting experiments that show that aging is amenable to medical intervention; we can slow it down and even reverse some age-related changes. As recent experiments on mice demonstrate, there are various ways to postpone aging. Among the most promising treatments are the elimination of harmful senescent cells, drugs that enhance metabolism, genetic and cellular therapies, and calorie restriction. These treatments extend the healthy period of life, and, as a welcome side effect, lifespan in mice by over 25–30%. Some of these methods are currently in human clinical trials and are expected to reach the market 5–10 years from now.

When the California two-spot octopus isn’t attempting to bring more eight-legged cephalopods into this world, it prefers to be alone. Known to scientists as Octopus bimaculoides, the alien-like invertebrate spends most of its time hiding from the world or searching for food, asocial males avoiding asocial females until their biological clocks say it’s time to partner up. That is, until they are on MDMA. In a groundbreaking study released Thursday, researchers describe how octopuses on the drug act similarly to a socially anxious human on MDMA: They open up.

Gül Dölen, Ph.D., is an assistant professor of neuroscience at Johns Hopkins University and the co-author of the new Current Biology paper. She tells Inverse that when octopuses are on MDMA, it’s like watching “an eight-armed hug.”

“They were very loose,” Dölen says. “They just embraced with multiple arms.”

James Peyer has been a scientist, entrepreneur, and advisor to biotechs and pharma companies, always with a specialization for developing new classes of therapeutics. James founded Apollo to support biotech entrepreneurs strategically, scientifically, and financially as they create the next generation of medicines.

James Peyer received his PhD from the University of Texas Southwestern Medical Center in Dallas, where he was a National Science Foundation Fellow and worked on the basic biology of stem cells and improving gene therapies. He founded his first company, Genotyp, at 21 to overhaul hands-on science education in the US. Genotyp’s innovative biotech equipment leasing model and instructor training earned it the approval of the White House and the National Institutes of Health. It became the first biotech company to receive funding through Kickstarter.com. He received a BA with special honors from the University of Chicago, where he studied immunology.

Discoveries in aging biology are ready for acceleration to the clinic, where they can treat age-related disease and extend healthy lifespan.

Continue reading “Interview with Apollo Ventures which funds anti-aging companies” »

All three of these surprising achievements are highlighted in the Goalkeepers 2018 Data Report, written by Bill and Melinda Gates and released on Sept. 18. But the dispatch—an assessment of the progress made so far on the United Nations’ 17 Sustainable Development Goals and done with the help of the University of Washington’s Institute for Health Metrics and Evaluation—is anything but rah-rah. For every encouraging data point, indeed, there is one that alarms. For every promising advance in the global war on poverty and disease is a perilous outcome if we lose focus or steam.

A report from the Bill & Melinda Gates Foundation focuses on four key areas: Health, education, sanitation, and family planning.

Researchers think it could play an important function in devices using IoT and medical applications.

Giving millions of patients already taking statins a new type of drug could slash their heart disease risk even further, research suggests.

Scientists claim pills that are currently under development, called lipoprotein lipase (LPL) enhancers, could prevent thousands of heart attacks.

Continue reading “Give millions of patients already on statins a new type of drug” »

Today, we want to draw your attention to a new study that looks at the role of chronic age-related inflammation and the decline of nerve regeneration.

Inflammaging drives age-related loss of tissue regeneration

Inflammation can be beneficial and serves an important purpose: it spurs regeneration and immune responses while combating pathogens and other invaders. This kind of inflammation tends to be short-lived and localized to an area of injury. However, there is another form of inflammation, a chronic, smouldering kind that accompanies aging: this is often called inflammaging.

Surging productivity and the general rise in incomes it brings would be welcome, of course, but that isn’t sufficient. The same questions being raised about the advance of robotics in the workplace apply to machine learning. While new jobs would be created, many existing jobs — from doctors and financial advisers to translators and call-center operators — are susceptible to displacement or much-reduced roles. No economic law guarantees that productivity growth benefits everyone equally. Unless we thoughtfully manage the transition, some people, even a majority, are vulnerable to being left behind even as others reap billions.

Whether it’s for the better and for the many is up to human intelligence.